[go: up one dir, main page]

MX2007015472A - Lipasas para uso farmaceutico. - Google Patents

Lipasas para uso farmaceutico.

Info

Publication number
MX2007015472A
MX2007015472A MX2007015472A MX2007015472A MX2007015472A MX 2007015472 A MX2007015472 A MX 2007015472A MX 2007015472 A MX2007015472 A MX 2007015472A MX 2007015472 A MX2007015472 A MX 2007015472A MX 2007015472 A MX2007015472 A MX 2007015472A
Authority
MX
Mexico
Prior art keywords
lipases
pharmaceutical use
diabetes type
protease
stable
Prior art date
Application number
MX2007015472A
Other languages
English (en)
Inventor
Allan Svendsen
Kim Borch
Peter Colin Gregory
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Publication of MX2007015472A publication Critical patent/MX2007015472A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere al uso farmaceutico de las lipasas relacionadas con una variante de la lipasa de Thermomyces lanuginosus (Humicola lanuginosa) que comprende los aminoacidos 1-269 de la SEC ID NO: 1, opcionalmente en combinacion con una proteasa y/o una amilasa. Los ejemplos de las indicaciones medicas son: el tratamiento de trastornos digestivos, insuficiencia pancreatica exocrina (PEI), pancreatitis, fibrosis quistica, diabetes del tipo I, y/o diabetes del tipo II. Las lipasas de la invencion tienen una eficacia mejorada in vivo, son estables contra la degradacion de la proteasa, y/o son estables en la presencia de las sales biliares.
MX2007015472A 2005-06-24 2006-06-16 Lipasas para uso farmaceutico. MX2007015472A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500929 2005-06-24
PCT/DK2006/000352 WO2006136159A2 (en) 2005-06-24 2006-06-16 Lipases for pharmaceutical use

Publications (1)

Publication Number Publication Date
MX2007015472A true MX2007015472A (es) 2008-04-17

Family

ID=34956781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015472A MX2007015472A (es) 2005-06-24 2006-06-16 Lipasas para uso farmaceutico.

Country Status (17)

Country Link
US (1) US20090047266A1 (es)
EP (1) EP1896577A2 (es)
JP (1) JP2008546394A (es)
KR (1) KR20080017025A (es)
CN (1) CN101208429A (es)
AR (1) AR053634A1 (es)
AU (1) AU2006261442A1 (es)
BR (1) BRPI0612274A2 (es)
CA (1) CA2612648A1 (es)
IL (1) IL187511A0 (es)
MX (1) MX2007015472A (es)
NO (1) NO20080437L (es)
NZ (1) NZ563693A (es)
RU (1) RU2007149045A (es)
TW (1) TW200738256A (es)
WO (1) WO2006136159A2 (es)
ZA (1) ZA200710643B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
RU2008102650A (ru) * 2005-06-24 2009-07-27 Новозимс А/С (Dk) Амилазы для фармацевтического применения
JP5140586B2 (ja) 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
CA2657272C (en) * 2006-07-13 2014-10-28 Dsm Ip Assets B.V. Use of bacterial amylases in feed for bovine animals
KR20090101930A (ko) * 2006-12-21 2009-09-29 노보자임스 에이/에스 약학적 사용을 위한 리파아제 변형체
WO2009071550A1 (en) 2007-12-04 2009-06-11 Novozymes A/S Protease variants for pharmaceutical use
MX2010007242A (es) * 2008-01-03 2010-10-05 Abbott Products Gmbh Composiciones farmaceuticas que comprenden granulos de lipasa microbiana purificada y metodos para prevenir o tratar trastornos digestivos.
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
GB2468629B (en) * 2008-06-08 2011-10-26 Tarig Sayed Mustafa Arbab Method, composition, device for the treatment of amylase malfunctions/inactivity in association with saccharides (mainly polysaccharides) based diseases
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
CN104024393A (zh) 2011-12-29 2014-09-03 诺维信公司 具有脂肪酶变体的洗涤剂组合物
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
GB201212932D0 (en) * 2012-07-20 2012-09-05 Dupont Nutrition Biosci Aps Method
GB201212934D0 (en) * 2012-07-20 2012-09-05 Dupont Nutrition Biosci Aps Method
CN103045559B (zh) * 2012-10-23 2014-05-14 浙江工业大学 疏绵状嗜热丝孢菌脂肪酶突变体、编码基因及其应用
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
EP2914611B1 (en) 2012-11-01 2018-08-29 Novozymes A/S Method for removal of dna
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
US10537122B2 (en) * 2013-12-17 2020-01-21 Alltech, Inc. Systems and methods for adjusting animal feed
US9672331B2 (en) * 2013-12-17 2017-06-06 Alltech, Inc. Systems and methods for computer models of animal feed
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
US20210251238A1 (en) * 2018-06-05 2021-08-19 Novozymes Bioag A/S Methods of protecting a plant from insect pests
CN115247166B (zh) * 2021-04-27 2025-11-25 南京百斯杰生物工程有限公司 一种蛋白酶突变体
PE20251535A1 (es) 2022-05-14 2025-06-05 Novozymes As Composiciones y metodos para prevenir, tratar, suprimir y/o eliminar infecciones e infestaciones fitopatogenas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5892013A (en) * 1990-09-13 1999-04-06 Novo Nordisk A/S Lipase variants
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
CA2279986A1 (en) * 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
ES2328429T3 (es) * 1998-11-27 2009-11-12 Novozymes A/S Variantes de enzimas lipoliticas.
EP1162995B1 (de) * 1999-03-17 2003-06-04 Solvay Pharmaceuticals GmbH Enzyme zur behandlung von diabetes mellitus typ i
US6939702B1 (en) * 1999-03-31 2005-09-06 Novozymes A/S Lipase variant
EP1428874B1 (en) * 1999-03-31 2013-12-18 Novozymes A/S Lipase variant
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
DE10260903A1 (de) * 2002-12-20 2004-07-08 Henkel Kgaa Neue Perhydrolasen
WO2004111216A2 (en) * 2003-06-19 2004-12-23 Novozymes A/S Phospholipase variants

Also Published As

Publication number Publication date
AR053634A1 (es) 2007-05-09
TW200738256A (en) 2007-10-16
RU2007149045A (ru) 2009-07-10
IL187511A0 (en) 2008-03-20
WO2006136159A2 (en) 2006-12-28
CA2612648A1 (en) 2006-12-28
BRPI0612274A2 (pt) 2016-09-06
NO20080437L (no) 2008-03-25
CN101208429A (zh) 2008-06-25
US20090047266A1 (en) 2009-02-19
WO2006136159A3 (en) 2007-04-12
KR20080017025A (ko) 2008-02-25
ZA200710643B (en) 2008-11-26
EP1896577A2 (en) 2008-03-12
AU2006261442A1 (en) 2006-12-28
NZ563693A (en) 2010-08-27
JP2008546394A (ja) 2008-12-25

Similar Documents

Publication Publication Date Title
TW200738256A (en) Lipases for pharmaceutical use
MX2009006597A (es) Variantes de lipasa para uso farmaceutico.
MX2007015471A (es) Amilasas para uso farmaceutico.
DK1755656T3 (da) Enzymer til farmaceutisk anvendelse
NO20080438L (no) Proteaser til farmasoytisk anvendelse
PT1729797E (pt) Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
GB2511713A (en) Methods of treating behavioral symptoms of neurological and mental disorders
HUP0500560A2 (hu) Mikróbás enzimek új keverékei
GB2497715A (en) Preparation and use of combination enzyme and gastriontestinal modulator delivery systems
JP2008521906A5 (es)
EP4413994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
IL209979A (en) Use of 70 hsp to prepare a drug to treat lysosomal storage disease
EP4241854A3 (en) Lysosomal storage disease enzyme
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
Wang et al. An acidophilic β-galactosidase from Bispora sp. MEY-1 with high lactose hydrolytic activity under simulated gastric conditions
AU2016208474B9 (en) Use of enzymes with a wide ph activity range as medicaments for promoting digestion
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721A (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721B (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten
WO2007057897A3 (en) Pharmaceutical composition and method for regulating abnormal cellular proliferation